MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Peritoneal (Abdominal Mesothelioma)

Malignant peritoneal mesothelioma; cancer of the lining of the abdominal caviety.

Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.

Journal of Translational Medicine 2018 July 13 [Link] Kittaneh M, Berkelhammer C Abstract Germline mutations in the BRCA-1 associated tumor protein 1 (BAP1) increase susceptibility to mesothelioma and other cancers. We describe a patient with a family history of peritoneal mesothelioma, who developed malignant peritoneal mesothelioma at age 45 in the absence of known asbestos […]

Comments Off on Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.

Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.

Annals of Surgical Oncology 2018 July 5 [Link] Malgras B, Gayat E, Aoun O, Dico RL, Eveno C, Pautrat K, Delhorme JB, Passot G, Marchal F, Sgarbura O, Ferron G, Goéré D, Andre T, Pocard M Abstract BACKGROUND: The introduction of cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) improved the prognosis of […]

Comments Off on Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.

Peritoneal Metastases from Malignant Mesothelioma.

Surgical Oncology Clinics of North America 2018 July [Link] Li CY, Alexander HR Jr Abstract Diffuse malignant peritoneal mesothelioma (MPM) is a rare cancer that is ultimately fatal in almost all afflicted individuals. Morbidity and mortality from MPM is due to its propensity to progress locoregionally within the abdominal cavity. Patients with MPM most commonly […]

Comments Off on Peritoneal Metastases from Malignant Mesothelioma.

Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.

Journal of Cellular Physiology 2018 June 15 [Link] Sementino E, Menges CW, Kadariya Y, Peri S, Xu J, Liu Z, Wilkes RG, Cai KQ, Rauscher FJ, Klein-Szanto AJ, Abstract Malignant mesothelioma (MM) is a therapy-resistant cancer arising primarily from the lining of the pleural and peritoneal cavities. The most frequently altered genes in human MM […]

Comments Off on Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.

Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.

Journal of the National Comprehensive Cancer Network 2018 June 16 [Link] Bochtler T, Endris V, Reiling A, Leichsenring J, Schweiger MR, Klein S, Stögbauer F, Goeppert B, Schirmacher P, Krämer A, Stenzinger A Abstract This case report presents a male patient with epithelioid mesothelioma that was initially misdiagnosed as cancer of unknown primary (CUP) and […]

Comments Off on Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.

Peritoneal Metastases from Gastrointestinal Cancer

Current Oncology Reports 2018 June 8 [Link] Sugarbaker PH Abstract PURPOSE OF REVIEW: Peritoneal metastases may occur from a majority of cancers that occur within the abdomen or pelvis. When cancer spread to the peritoneal surfaces is documented, a decision regarding palliation vs. an aggressive approach using cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy must […]

Comments Off on Peritoneal Metastases from Gastrointestinal Cancer

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

The Lancet. Respiratory Medicine. 2018 May 14 [Link] Calabrò L, Morra A, Giannarelli D, Amato G, D’Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, Di Giacomo AM, Maio M Abstract BACKGROUND: Tremelimumab, an anti-CTLA4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve […]

Comments Off on Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival

Annals of surgical oncology 2018 May [Link] Verma V, Sleightholm RL, Rusthoven CG, Koshy M, Sher DJ, Grover S, Simone CB Abstract PURPOSE: This study of a large, contemporary national database evaluated management patterns, outcomes, and prognostic factors of malignant peritoneal mesothelioma (MPM) in the USA. METHODS: The National Cancer Data Base was queried for […]

Comments Off on Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival

Malignant Peritoneal Mesothelioma Presenting as Mucinous Ascites

ACG Case Reports Journal 2018 March [Link] Field Z, Zori A, Khullar V, Mota M, Feely M, Firpi RJ Abstract We present a rare case of a 46-year-old man presenting with mucinous ascites secondary to malignant peritoneal mesothelioma (MPM) that was diagnosed via colonoscopy with biopsies. Both our findings and the clinical presentation were unique. […]

Comments Off on Malignant Peritoneal Mesothelioma Presenting as Mucinous Ascites

Value of immunocytochemistry in differential diagnosis of gastric adenocarcinoma, reactive mesothelial cells and malignant epithelial mesothelioma in metastatic effusion fluid

Chinese Journal of Pathology 2018 March [Link] Lyu M, Cha N, Zou YF, Leng JH, Xu L, Sun Y, Hao YY Abstract Objective: To investigate the diagnostic value of some antibodies in peritoneal fluid of patients with gastric cancer and malignant epithelioid mesothelioma in serous effusion. Methods: One hundred and eighty-two cases of serous effusion […]

Comments Off on Value of immunocytochemistry in differential diagnosis of gastric adenocarcinoma, reactive mesothelial cells and malignant epithelial mesothelioma in metastatic effusion fluid